News | September 02, 2021
Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Domestic business was up 41.9% YoY and 27.7% QoQ
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Anti-malaria API facility will be operational in 15-18 months
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Arch Pharma Labs has filed the application
Robust demand for the product across the Middle East, Africa and Latin America
Subscribe To Our Newsletter & Stay Updated
